$ISRG

Is Wall Street Bullish or Bearish on Intuitive Surgical Stock?

Analysts maintain positive outlook on Intuitive Surgical (ISRG), with Citigroup's Joanne Wuensch setting a $500 price target, implying 33.5% upside. The mean target is $483.34, with a high of $685, suggesting 82.9% potential gain.

Original reporting
Published Aug 22, 2026, 2:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 22, 2026, 2:23 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Is Wall Street Bullish or Bearish on Intuitive Surgical Stock? — source image
Decision brief

The 30-second read

$ISRGBullishMed
01

Why it matters

The maintained Buy rating with higher targets suggests confidence in growth, likely prompting price rally.

02

Market read

Analyst target revisions are a common catalyst for short-term price moves in healthcare equities.

03

What to watch

Potential regulatory or reimbursement challenges not addressed.

Relevance 7/10Novelty 6/10Timing: today

Background

Intuitive Surgical is a leading provider of robotic surgical systems; analyst coverage influences its valuation.

Company-level read

Ticker impact

$ISRGBullishHigh confidence
Context

Citigroup analyst maintains Buy rating with new price targets of $500 and $685 for Intuitive Surgical.

Expected impact

Short-term bullish pressure as investors adjust models to higher targets.

Evidence & confidence

Analyst upgrade with specific price targets provides a clear actionable signal.

Market effects

Positive outlook may lift other robotic surgery and medical device stocks.

Limited to US healthcare sector.

Minor, confined to investors tracking Intuitive Surgical.

Counterpoint

Targets may be overly optimistic given competitive pressures.

Key entities

  • Citigroup Inc.

    Provides equity research coverage on ISRG.

Related articles

$ABTMed

Abbott vs. Intuitive Surgical: Which MedTech Stock Offers Better Long-Term Upside?

Abbott Laboratories (NYSE:ABT) and Intuitive Surgical (NASDAQ:ISRG) reported strong quarterly results, with Abbott raising its annual profit outlook and Intuitive beating revenue and earnings expectations. Abbott's diversification across diagnostics, medical devices, and nutrition drove growth, while Intuitive's robotic surgery ecosystem and recurring revenue model supported its performance. Despite the positive results, Intuitive's shares declined due to slowing domestic procedure growth. Abbot

$DHRMedAI 8/10

Danaher vs. Intuitive Surgical: Is Recovery or Innovation the Better Long-Term Bet?

Danaher (DHR) and Intuitive Surgical (ISRG) present contrasting growth paths. Danaher benefits from improving life sciences spending, with strong bioprocessing orders and $100M revenue shifted to next year. Intuitive Surgical reports 18% YoY growth in da Vinci system placements, 70% non-GAAP gross margin, and 85% recurring revenue. Investors must decide between cyclical recovery and structural growth.

$ISRGMed

Johnson & Johnson and Medtronic Enter the Fray, Squeezing Market Share as Intuitive Surgical Faces Its Biggest Challenge in Recent Years

Intuitive Surgical (ISRG) stock fell 30% in 2026 due to weak guidance, competition, and high valuations. Q2 revenue grew 19%, but full-year procedure growth guidance was below expectations. Competitors like Johnson & Johnson and Medtronic are entering the market, raising concerns about ISRG's market share. Analysts note high valuation multiples and slowing growth may pressure the stock further.

$ISRGMed

Oppenheimer Just Upgraded Intuitive Surgical Stock. Here's Why.

Oppenheimer upgraded Intuitive Surgical (ISRG) from “Perform” to “Outperform” and set a $500 price target, implying about 24.6% upside, citing robotic surgery growth and AI plans. The article notes Q2 revenue of $2.89B (vs $2.82B expected), EPS $2.80, da Vinci and Ion procedure growth, and ISRG guidance for da Vinci growth of 13.5% to 15.5%.

$ISRGMed

Why is Intuitive Surgical stock gaining today?

Investing.com reports Intuitive Surgical (ISRG) rose about 0.8% in pre-open after Oppenheimer upgraded it to Outperform from Perform and set a $500 price target. Oppenheimer and Bank of America Securities issued Buy ratings, citing da Vinci’s competitive position and Per Click Model. The article also notes ISRG Q2 2026 EPS of $2.80 vs $2.51 consensus.